In Silico Biosciences, Inc. (ISB), since 2000, has been using advanced mathematical techniques, computational neuroscience, and pharmaceutical concepts to focus on diseases of the central nervous system. ISB uses Quantitative Systems Pharmacology (QSP), involving complex computer-based models of firing activity in biophysical neuronal circuits, to support central nervous system research and development, making modeled results actionable with practical applications.
In 2020, ISB joined the QSPainRelief Consortium whose partners include academics, clinicians, companies, and patient organizations which bring together the necessary and complementary expertise to understand chronic pain and drug action for analgesia and treatment side-effects. ISB assembled its existing and new in silico computational models to evaluate combinations of existing drugs that provide efficacy (increased pain relief) and lesser side effects (sedation, cognitive impairment, and drug abuse liability), yielding real-world value for individual patients.
NewCo, Inc. was formed as a subsidiary company of ISB in 2024 to develop and distribute an intuitive, user-friendly electronic decision support platform for use by Pain Management Clinicians.
The Prescribing Support Tool is an innovative, highly integrative, and multi-disciplinary decision support platform designed to predict pain relief and side effects of combination drug therapies. It makes use of data obtained from cellular, preclinical, and clinical studies, which are integrated by systems modeling approaches to understand the pathophysiology of pain in groups of patients responding well or poorly to particular combination therapies. The platform assembles proprietary computational models into a highly sophisticated framework for predicting patient responses to new combination therapies. In the hands of Pain Management Clinicians, the Prescribing Support Tool makes better use of human intellectual capital to support the prescription of optimally effective and safe combination therapies for individual patients with chronic pain.